Article Text

  1. A. Stavrakis,
  2. R. Barndt
  1. Los Angeles, CA.


Calcium and hormonal replacement therapy (Cal-HRRx) increased adrenergic neurovascular tone (ANVT), systemic vascular resistance (SVR) and NV symptom levels (SL) in 50% of our pilot study (PS). In prospective studies (ProS) serial measurements (SM) were made of: systolic time intervals (STI), SBP, rise in pulse pressure to handgrip (RPPHg, 5 PSI, 3 min), systemic vascular resistance (SVR), and cardiac output (CO) by echo. NVT SL (i.e.: migraine, paresthesias, chest wall SL, etc.) were assessed by the quality of life (QL, 0-100%). STI monitored ANVT (STI=PEP/LVET X 100%). The parameters were studied by: SVR = (mean BP-6) X 80/CO, using standard units. In ProS women with type A/AX/B behavior were randomized from the general population (GenP) into 100/ group (G) with normal CO (4 -7 L/min). A subgroup of type A (SA) with low BP (≤100 mmHg) and CO (≤4) were studied as a G. All women were: postmenopausal, age 55±5, with STI levels at low stress PS G means ± 2, and SBP 110±10 mmHg. Type B women were age-matched controls on the Rx protocol. Daily Cal-HRRx was: 1500 mg Cal, 0.625 estrogen and 2.5 mg progesterone in each G on a double blind placebo cross-over protocol (3mo. each). Data was collected at time 1 (T1=low stress on dietary Cal at 500 mg/day and placebo) and T2 on Cal-HRRx, both at 2 week intervals for 12 weeks. Standard ultrasonic measurements (UM) were made at T1 and T2 (end). Data was placed into a blind matrix for analysis later. ProS G analysis: G means shown. (Table)

Where: * = Significant (Sig) difference from GB at P≤0.01 and ** = Sig change from T1 at P≤0.02, both by T test. % = % of total # cases. %NC = %Non-compliance (left study due to high SL). Sig** coronary risk occurred in GA (38% of GenP) due to SBP and ANVT (proven in parallel long-term studies by serial UM, R=0.97, P≤0.001) with Sig** increase in SL during Rx. A RPPHg ≥15 before Rx predicted type A women at risk (R=0.98, P≤0.001). The SA G had decreased SBP but increased coronary risk due to Sig** ANVT increase (STI change) on Rx (proven in long-term parallel studies, R=0.97, P≤0.001). Thus, Cal-HRRx is found to cause Sig vascular risk in 50% of the GenP due to increases in ANVT in type A women.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.